Patent thickets in malaria vaccine development

If next-stage malaria vaccines work (the primary challenge), they are likely to be based on multiple antigens, adjuvants, and other vaccine technology platforms.  Will intellectual property limitations, in the form of competing claims across a number of public and private players (the aptly named patent thicket), impede their development, commercialization, or access? Here’s a neat Rockefeller funded report for the Malaria Vaccine Initiative – 61% of malaria vaccine related patents are held by companies, 18% are available to the organization, and another 20% are available for public licensing. Another example of the intersection between public health and law.



%d bloggers like this: